Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16045
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, YY-
dc.contributor.authorSnyder, PJ-
dc.contributor.authorPietrzak, RH-
dc.contributor.authorUkigi, A-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorAmes, David-
dc.contributor.authorSalvado, O-
dc.contributor.authorBourgeat, P-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMaruff, Paul-
dc.date.accessioned2016-06-20T05:07:08Z-
dc.date.available2016-06-20T05:07:08Z-
dc.date.issued2015-12-12-
dc.identifier.citationAlzheimer's & Dementia (Amst) 2016; 2: 19-26en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16045-
dc.description.abstractINTRODUCTION: Cognitive composite scores developed for preclinical Alzheimer's disease (AD) often consist of multiple cognitive domains as they may provide greater sensitivity to detect β-amyloid (Aβ)-related cognitive decline than episodic memory (EM) composite scores alone. However, this has never been empirically tested. We compared the rate of cognitive decline associated with high Aβ (Aβ+) and very high Aβ (Aβ++) in cognitively normal (CN) older adults on three multidomain cognitive composite scores and one single-domain (EM) composite score. METHODS: CN older adults (n = 423) underwent Aβ neuroimaging and completed neuropsychological assessments at baseline, and at 18-, 36-, 54-, and 72-month follow-ups. Four cognitive composite scores were computed: the ADCS-PACC (ADCS-Preclinical Alzheimer Cognitive Composite), ADCS-PACC without the inclusion of the mini-mental state examination (MMSE), an EM composite, and the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults (ZAVEN) composite. RESULTS: Compared with Aβ+ CN older adults, Aβ++ CN older adults showed faster rates of decline across all cognitive composites, with the largest decline observed for ZAVEN composite (d = 1.07). Similarly, compared with Aβ- CN older adults, Aβ+ CN older adults also showed faster rates of cognitive decline, but only for the ADCS-PACC no MMSE (d = 0.43), EM (d = 0.53), and ZAVEN (d = 0.50) composites. DISCUSSION: Aβ-related cognitive decline is best detected using validated neuropsychological instruments. Removal of the MMSE from the ADCS-PACC and replacing it with a test of executive function (verbal fluency; i.e., the ZAVEN) rendered this composite more sensitive even in detecting Aβ-related cognitive decline between Aβ+ and Aβ++ CN older adults.en
dc.subjectAmyloiden
dc.subjectCognitive compositeen
dc.subjectCognitive declineen
dc.subjectNeuropsychological assessmenten
dc.subjectPreclinical Alzheimer's diseaseen
dc.titleSensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite scoreen
dc.typeJournal Articleen
dc.identifier.journaltitleAlzheimer's & Dementia (Amsterdam, Netherlands)en
dc.identifier.affiliationCommonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BioMedIA, Brisbane, Queensland, Australiaen
dc.identifier.affiliationDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USAen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australiaen
dc.identifier.affiliationCogstate Ltd., Melbourne, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationDepartment of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA; Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USAen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27239532en
dc.identifier.doi10.1016/j.dadm.2015.11.003en
dc.type.contentTexten
dc.type.austinJournal Articleen_US
local.name.researcherMasters, Colin L
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

30
checked on Nov 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.